Entero Therapeutics (Nasdaq:ENTO) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ENTO Overzicht aandelen

ENTO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 2.3% per jaar gegroeid

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $1M )

+ 1 meer risico

Entero Therapeutics, Inc. Concurrenten

Vyant Bio

OTCPK:VYNT

US$1.1m

GRI Bio

NasdaqCM:GRI

US$980.2k

Genprex

NasdaqCM:GNPX

US$1.3m

Histogen

OTCPK:HSTO

US$929.1k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Entero Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.33
52 Week Hoogtepunt	US$14.51
52 Week Laag	US$0.18
Bèta	1.37
11 maand verandering	-20.36%
3 maanden verandering	-67.14%
1 Jaar Verandering	-94.50%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Rendement voor aandeelhouders

	ENTO	US Biotechs	US Markt
7D	0.5%	-0.2%	-0.4%
1Y	-94.5%	22.1%	34.1%

Rendement versus industrie: ENTO presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 21.7 % opleverde.

Rendement versus markt: ENTO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.

Prijsvolatiliteit

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	24.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ENTO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 25% ) van ENTO is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	9	James Sapirstein	www.enterothera.com

Entero Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van doelgerichte en oraal toegediende therapieën voor de behandeling van patiënten met gastro-intestinale ziekten. De pijplijnkandidaten van het bedrijf omvatten latiglutenase, een doelgericht oraal biotherapeuticum voor coeliakie dat gluten moet afbreken in niet-immunogene peptiden, momenteel in Fase 2-studies; en capeserod, een selectieve partiële agonist van de 5-HT4-receptor in Fase 1-studies voor de behandeling van gastroparese. Het is ook betrokken bij de ontwikkeling van adrulipase, een recombinant lipase-enzym dat is ontwikkeld om de vertering van vetten en andere voedingsstoffen mogelijk te maken, momenteel in Fase 2-studies voor de behandeling van exocriene pancreasinsufficiëntie bij patiënten met cystische fibrose en chronische pancreatitis; en niclosamide, een orale kleine molecule met ontstekingsremmende therapie, momenteel in Fase 2-studies voor de behandeling van ulceratieve proctitis en ulceratieve proctosigmoiditis, evenals immuuncheckpointinhibitor-geassocieerde colitis en diarree bij patiënten met uitgezaaide kanker.

Entero Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Entero Therapeutics zich tot de beurswaarde?
ENTO fundamentele statistieken
Marktkapitalisatie	US$1.04m
Inkomsten(TTM)	-US$6.44m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is ENTO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ENTO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$6.44m
Inkomsten	-US$6.44m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.98
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	8.7%

Hoe presteerde ENTO op de lange termijn?

Bekijk historische prestaties en vergelijking

ENTO Overzicht aandelen

Beloningen

Risicoanalyse

Entero Therapeutics, Inc. Concurrenten

OTCPK:VYNT

US$1.1m

NasdaqCM:GRI

US$980.2k

NasdaqCM:GNPX

US$1.3m

OTCPK:HSTO

US$929.1k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

Recent updates

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency